Nowadays, mTOR inhibitors (rapamycin), such as sirolimus and everolimus, have been reported to be anti-recurrence/metastasis and improve the prognosis of patients who underwent LT for HCC (29). Here, MTOR is linked to hepatocellular carcinoma.